-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 18, the CDE official website showed that QLS31906, a class 1 biological drug for injection of Qilu Pharma, has obtained an implied license for clinical trials and is intended to be used for the treatment of malignant tumors
.
QLS31906 for injection is Qilu Pharma's first Class 1 new drug approved for clinical use this year.
The company has 24 Class 1 new drugs in the research pipeline and is in the stage of clinical application and above
.
QLS31906 for Class 1 biological drug injection is intended to be used for the treatment of malignant tumors, and the field of tumor treatment has become the resident field of Qilu Pharmaceutical's innovative research and development
.
Shortly after "taking over" in 2022, Qilu Pharmaceutical has already applied for clinical application of 3 Class 1 biological drugs, including QL1706 injection, QLS21908 for injection, and QL1604 injection, of which QLS21908 for injection is the first to apply for clinical application
.
In terms of clinical trials, QLS31906 for injection is Qilu Pharma's first Class 1 new drug approved for clinical use this year
.
According to data from Minet.
com, the domestic anti-tumor drug market has continued to expand in recent years.
In 2020, the sales of terminal anti-tumor drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 100 billion.
In the first half of 2021, its sales exceeded 57 billion yuan, a year-on-year increase of 17.
74%
.
Chemical sales of terminal anti-tumor drugs in Chinese public medical institutions (unit: ten thousand yuan) Source : Minet At present, Qilu Pharma has 24 Class 1 new drugs in the pipeline of clinical application and above, including 18 macromolecular biological drugs, involving monoclonal antibody, double antibody and ADC
.
The company's first class 1 new drug, ALK/ROS1 inhibitor, Iluoke Tablets, has applied for NDA in July 2021, and is expected to be approved for marketing as soon as this year
.
.
QLS31906 for injection is Qilu Pharma's first Class 1 new drug approved for clinical use this year.
The company has 24 Class 1 new drugs in the research pipeline and is in the stage of clinical application and above
.
QLS31906 for Class 1 biological drug injection is intended to be used for the treatment of malignant tumors, and the field of tumor treatment has become the resident field of Qilu Pharmaceutical's innovative research and development
.
Shortly after "taking over" in 2022, Qilu Pharmaceutical has already applied for clinical application of 3 Class 1 biological drugs, including QL1706 injection, QLS21908 for injection, and QL1604 injection, of which QLS21908 for injection is the first to apply for clinical application
.
In terms of clinical trials, QLS31906 for injection is Qilu Pharma's first Class 1 new drug approved for clinical use this year
.
According to data from Minet.
com, the domestic anti-tumor drug market has continued to expand in recent years.
In 2020, the sales of terminal anti-tumor drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 100 billion.
In the first half of 2021, its sales exceeded 57 billion yuan, a year-on-year increase of 17.
74%
.
Chemical sales of terminal anti-tumor drugs in Chinese public medical institutions (unit: ten thousand yuan) Source : Minet At present, Qilu Pharma has 24 Class 1 new drugs in the pipeline of clinical application and above, including 18 macromolecular biological drugs, involving monoclonal antibody, double antibody and ADC
.
The company's first class 1 new drug, ALK/ROS1 inhibitor, Iluoke Tablets, has applied for NDA in July 2021, and is expected to be approved for marketing as soon as this year
.
